This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
In vitro Antiviral Activity of Kabasura Kudineer - Siddha Polyherbal Formulation Against Novel Coronavirus (SARS-CoV-2) (preprint)
ssrn; 2021.
Preprint
in English
| PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.3842077
ABSTRACT
Kabasura Kudineer (KSK) is a Sastric Siddha polyherbal formulation that has been used to treat the fever with influenza-like indication. The purpose of this study is to validate the antiviral activity of KSK against the novel SARS-CoV-2 virus. The antiviral activity of KSK against SARS-CoV-2 was assessed in Vero E6 cells and followed by an RT-PCR assay. KSK significantly inhibited SARS-CoV-2 replication in Vero E6 cells. These data indicate that KSK prevents the attack of its virus, rendering the use of these a novel COVID-19 infectious diseases strategy.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-SSRN
Main subject:
COVID-19
Language:
English
Year:
2021
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS